All In Biotech

Drug Trial Radar · NCT03163966

A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

A Randomized, Double Blind, Placebo-controlled, Dose Response, Phase II, Multicentre Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Oral CR6086 Administered at the Doses of 30, 90 or 180 mg Bid for 12 Weeks in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Oct 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 248 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

248

Actual

Start

Oct 5, 2017

Primary completion

Jan 8, 2019

Study completion Jan 8, 2019

Sponsor

Lead sponsor
Rottapharm BiotechIndustry
Sponsor type
Industry
First posted
May 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CR6086 is a new, potent and selective, orally available, small molecule prostaglandin EP4 receptor antagonist, endowed with immunomodulatory properties. The pharmacological properties of CR6086, along with its oral bioavailability, predictable pharmacokinetics and good safety, make it the ideal candidate to be tested alone or in combination with methotrexate (MTX) in patients with early Rheumatoid Arthritis who are naïve to Disease-Modifying Antirheumatic Drugs (DMARDs). The compound has indeed the potential to provide a safer and more effective treatment than MTX (or other conventional synthetic DMARDs - csDMARDs), and could significantly improve the proportion of responder patients and avoid/delay the recourse to biological DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs).

Conditions

  • Rheumatoid Arthritis, DMARD-naive and Early Disease Patients

Interventions

  • CR6086Drug

    oral CR6086 capsules

  • MethotrexateDrug

    oral Methotrexate tablets

  • PlaceboDrug

    oral CR6086 Placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. American College of Rheumatology 20% improvement (ACR20) responder rateTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Rheumatology

    Prague, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.